Eli Lilly and AbCellera’s Bamlanivimab (LY-CoV555) and Etesevimab (LY-CoV016) Receive the US FDA’s EUA for COVID-19

February 10, 2021 Auto Bot AbCellera, Eli Lilly, EUA, FDA, receives, regulatory 0

Shots:

  • The FDA authorized EUA for bamlanivimab (700 mg) and etesevimab (1400 mg) for the treatment of mild to mod. COVID-19 patients aged ≥12yrs. who are at high risk for progressing to severe COVID-19 and/or hospitalization
  • The EUA is based on P-III BLAZE-1 trial in ≥1,000 COVID-19 patients showed 70% reduction in hospitalizations. Lilly plans to manufacture 250,000+ doses in Q1’ 21 and up to 1M doses by mid-2021
  • The FDA authorizes new protocols for infusion of bamlanivimab as monothx. and bamlanivimab and etesevimab together in as few as 16 and 21 min respectively

Click here ­to­ read full press release/ article | Ref: Businesswire | Image: Genetic Engineering and Biotechnology News

The post Eli Lilly and AbCellera’s Bamlanivimab (LY-CoV555) and Etesevimab (LY-CoV016) Receive the US FDA’s EUA for COVID-19 first appeared on PharmaShots.